Serine/threonine kinases as molecular targets of antidepressants: implications for pharmacological treatment and pathophysiology of affective disorders

被引:25
|
作者
Popoli, M
Mori, S
Brunello, N
Perez, J
Gennarelli, M
Racagni, G
机构
[1] Univ Milan, Dept Pharmacol Sci, Ctr Neuropharmacol, I-20133 Milan, Italy
[2] Univ Modena, Dept Pharmaceut Sci, I-41100 Modena, Italy
[3] Univ Vita & Salute, Dept Neuropsychiat, Ist Sci HSR, I-20127 Milan, Italy
[4] FBF, Ctr S Giovanni di Dio, IRCCS, Brescia, Italy
关键词
protein kinase; antidepressant; CaM kinase; cAMP-dependent kinase; synaptotagmin; synaptic plasticity;
D O I
10.1016/S0163-7258(00)00108-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It is currently a widely accepted opinion that adaptive. plastic changes in the molecular and cellular components of neuronal signaling systems correlate with the effects on mood and cognition observed after long-term treatment with antidepressant drugs. Protein phosphorylation represents a key step for most signaling systems, and it is involved in the regulation of virtually all cellular functions. Two serine/threonine kinases. Ca(2+)/calmodulin-dependent protein kinase II and cyclic AMP-dependent protein kinase. have been shown to be activated in the brain following antidepressant treatment. The changes in kinase activity are mirrored by changes in the phosphorylation of selected protein substrates in subcellular compartments (presynaptic terminals and microtubules), which, in rum, ma), contribute to the modulation of synaptic transmission observed with antidepressants. The molecular consequences of protein kinase activation may account for some of the alterations in neural function induced by antidepressants, and may suggest novel possible strategies of pharmacological intervention. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:149 / 170
页数:22
相关论文
共 50 条
  • [1] Abnormalities of cAMP signaling in affective disorders: implications for pathophysiology and treatment
    Perez, J
    Tardito, D
    Mori, S
    Racagni, G
    Smeraldi, E
    Zanardi, R
    [J]. BIPOLAR DISORDERS, 2000, 2 (01) : 27 - 36
  • [2] The serine/threonine kinases that control cell cycle progression as therapeutic targets
    Diallo, Alghassimou
    Prigent, Claude
    [J]. BULLETIN DU CANCER, 2011, 98 (11) : 1335 - 1345
  • [3] Molecular targets for affective disorders and anxiety
    Schoepp, Darryle D.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S5 - S5
  • [4] Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia
    Uckun, FM
    Mao, C
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (10) : 1083 - 1091
  • [5] PHARMACOLOGICAL TREATMENT OF AFFECTIVE-DISORDERS
    BECKMANN, H
    [J]. NERVENARZT, 1981, 52 (03): : 135 - 146
  • [6] Targeting the messengers: Serine/threonine protein kinases as potential targets for antimycobacterial drug development
    Khan, Mehak Zahoor
    Kaur, Prabhjot
    Nandicoori, Vinay Kumar
    [J]. IUBMB LIFE, 2018, 70 (09) : 889 - 904
  • [7] GR-regulating Serine/Threonine Kinases: New Physiologic and Pathologic Implications
    Kino, Tomoshige
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2018, 29 (04): : 260 - 270
  • [8] Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders
    McEwen, BS
    Magarinos, AM
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2001, 16 : S7 - S19
  • [9] Autophagy and affective disorders: pharmacological and molecular studies
    Kara, N.
    Luczak, T.
    Agam, G.
    Anderson, G.
    Einat, H.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S775 - S776
  • [10] Chronic Pain, Affective Spectrum Disorders and Treatment with Antidepressants
    Todorovic, M.
    Timotijevic, I.
    Crnic, K.
    [J]. EUROPEAN PSYCHIATRY, 2015, 30